CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
1 - 29 . (canceled)
30 . A conjugate having a formula
B-L-(D) n
or a pharmaceutically acceptable salt thereof;
wherein B comprises a urea of lysine and glutamic acid;
wherein L is a polyvalent linker;
wherein D comprises a radioactive isotope of a metal coordinated to a chelating group; and
wherein n is 1.
31 . The conjugate of claim 30 or the pharmaceutically acceptable salt thereof, wherein B comprises a structure
32 . The conjugate of claim 30 or the pharmaceutically acceptable salt thereof, wherein B is selected from the group consisting of
33 . The conjugate of claim 30 or the pharmaceutically acceptable salt thereof, wherein B is selected from the group consisting of
34 . The conjugate of claim 30 or the pharmaceutically acceptable salt thereof, wherein B is selected from the group consisting of
35 . The conjugate of claim 30 or the pharmaceutically acceptable salt thereof, wherein L forms a urea with the lysine.
36 . The conjugate of claim 30 or the pharmaceutically acceptable salt thereof, wherein L comprises a chain of at least about 7 atoms.
37 . The conjugate of claim 30 or the pharmaceutically acceptable salt thereof, wherein L comprises a chain of at least about 8 atoms.
38 . The conjugate of claim 30 or the pharmaceutically acceptable salt thereof, wherein L comprises a chain of at least about 9 atoms.
39 . The conjugate of claim 30 or the pharmaceutically acceptable salt thereof, wherein L comprises a chain of at least 10 atoms.
40 . The conjugate of claim 30 or the pharmaceutically acceptable salt thereof, wherein the linker comprises an alkylene, a cycloalkylene, an alkylenecycloalkyl, an alkylenecarbonyl, or a cycloalkylenecarbonyl.
41 . The conjugate of claim 40 or the pharmaceutically acceptable salt thereof, wherein the alkylene, the cycloalkylene, the alkylenecycloalkyl, the alkylenecarbonyl, and the cycloalkylenecarbonyl are each independently optionally substituted with one or more substituents X 1 selected from the group consisting of aryl, substituted aryl, arylalkyl, and substituted arylaklyl.
42 . The conjugate of claim 41 or the pharmaceutically acceptable salt thereof, wherein X 1 comprises naphthyl.
43 . The conjugate of claim 30 or the pharmaceutically acceptable salt thereof, wherein B-L comprises a diradical of the formula
44 . A conjugate having a formula
B-L-D
or a pharmaceutically acceptable salt thereof;
wherein B comprises a urea of lysine and glutamic acid, and wherein B comprises a structure
wherein L is a polyvalent linker, wherein L forms a urea with the lysine, and wherein L comprises an alkylene, a cycloalkylene, an alkylenecycloalkyl, an alkylenecarbonyl, or a cycloalkylenecarbonyl; and
wherein D comprises a radioactive isotope of a metal coordinated to a chelating group.
45 . The conjugate of claim 44 or the pharmaceutically acceptable salt thereof, wherein the alkylene, the cycloalkylene, the alkylenecycloalkyl, the alkylenecarbonyl, and the cycloalkylenecarbonyl are each independently optionally substituted with one or more substituents X 1 selected from the group consisting of aryl, substituted aryl, arylalkyl, and substituted arylaklyl.
46 . The conjugate of claim 45 or the pharmaceutically acceptable salt thereof, wherein X 1 comprises naphthyl.
47 . The conjugate of claim 44 or the pharmaceutically acceptable salt thereof, wherein B is selected from the group consisting of
48 . The conjugate of claim 44 or the pharmaceutically acceptable salt thereof, wherein B is selected from the group consisting of
49 . The conjugate of claim 44 or the pharmaceutically acceptable salt thereof, wherein B is selected from the group consisting of